These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 19899394)

  • 1. [Vaccination: cost-effectiveness ratio].
    Swennen B
    Rev Med Brux; 2009 Sep; 30(4):451-7. PubMed ID: 19899394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. WHO Guide for standardisation of economic evaluations of immunization programmes.
    Walker DG; Hutubessy R; Beutels P
    Vaccine; 2010 Mar; 28(11):2356-9. PubMed ID: 19567247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health economic research on vaccinations and immunisation practices--an introductory primer.
    Szucs TD
    Vaccine; 2005 Mar; 23(17-18):2095-103. PubMed ID: 15755578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do we fully understand the economic value of vaccines?
    Drummond M; Chevat C; Lothgren M
    Vaccine; 2007 Aug; 25(32):5945-57. PubMed ID: 17629362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New vaccines against otitis media: projected benefits and cost-effectiveness.
    O'Brien MA; Prosser LA; Paradise JL; Ray GT; Kulldorff M; Kurs-Lasky M; Hinrichsen VL; Mehta J; Colborn DK; Lieu TA
    Pediatrics; 2009 Jun; 123(6):1452-63. PubMed ID: 19482754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of the cost-effectiveness of varicella vaccine programmes based on an observational survey in the Latium region of Italy.
    Gialloreti LE; Divizia M; Pica F; Volpi A
    Herpes; 2005 Oct; 12(2):33-7. PubMed ID: 16209858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human health benefits from livestock vaccination for brucellosis: case study.
    Roth F; Zinsstag J; Orkhon D; Chimed-Ochir G; Hutton G; Cosivi O; Carrin G; Otte J
    Bull World Health Organ; 2003; 81(12):867-76. PubMed ID: 14997239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health care costs of diarrheal disease and estimates of the cost-effectiveness of rotavirus vaccination in Vietnam.
    Fischer TK; Anh DD; Antil L; Cat ND; Kilgore PE; Thiem VD; Rheingans R; Tho le H; Glass RI; Bresee JS
    J Infect Dis; 2005 Nov; 192(10):1720-6. PubMed ID: 16235169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Vaccination--value for money?].
    Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Kristiansen IS
    Tidsskr Nor Laegeforen; 2006 Oct; 126(20):2670-3. PubMed ID: 17057767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness and potential impact of rotavirus vaccination in the United States.
    Widdowson MA; Meltzer MI; Zhang X; Bresee JS; Parashar UD; Glass RI
    Pediatrics; 2007 Apr; 119(4):684-97. PubMed ID: 17403839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [National economic consequences of vaccines].
    Bergman A; Persson U
    Lakartidningen; 2008 May 28-Jun 3; 105(22):1680-4. PubMed ID: 18590011
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
    Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
    Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging issues in vaccine economics: perspectives from the USA.
    Lieu TA; Thompson KM; Prosser LA; O'Brien MA; Yusuf HR; Shefer AM; Weinstein MC; Rickert DL
    Expert Rev Vaccines; 2002 Dec; 1(4):433-42. PubMed ID: 12901581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of the pneumococcal vaccine in the United States Navy and Marine Corps.
    Vold Pepper P; Owens DK
    Clin Infect Dis; 2000 Jan; 30(1):157-64. PubMed ID: 10619745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic review of economic evaluation analyses of available vaccines in Spain from 1990 to 2012.
    Cortés I; Pérez-Camarero S; Del Llano J; Peña LM; Hidalgo-Vega A
    Vaccine; 2013 Aug; 31(35):3473-84. PubMed ID: 23764534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic costs of rotavirus gastroenteritis and cost-effectiveness of vaccination in developing countries.
    Rheingans RD; Antil L; Dreibelbis R; Podewils LJ; Bresee JS; Parashar UD
    J Infect Dis; 2009 Nov; 200 Suppl 1():S16-27. PubMed ID: 19817595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of a potential prophylactic Helicobacter pylori vaccine in the United States.
    Rupnow MF; Chang AH; Shachter RD; Owens DK; Parsonnet J
    J Infect Dis; 2009 Oct; 200(8):1311-7. PubMed ID: 19751153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of human papillomavirus vaccination in Belgium: do not forget about cervical cancer screening.
    Thiry N; De Laet C; Hulstaert F; Neyt M; Huybrechts M; Cleemput I
    Int J Technol Assess Health Care; 2009 Apr; 25(2):161-70. PubMed ID: 19366497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-benefit analysis of hepatitis B vaccination.
    Jönsson B
    Postgrad Med J; 1987; 63 Suppl 2():27-32. PubMed ID: 3120169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation.
    Tilson L; Thornton L; O'Flanagan D; Johnson H; Barry M
    Eur J Public Health; 2008 Jun; 18(3):275-82. PubMed ID: 18160389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.